Report
Alexander Aukner ...
  • Karl-Johan Bonnevier
  • Martin Arnell
  • Mats Bye
  • Nicolai Farstad Olsen
  • Ole-Andreas Krohn
  • Patrik Ling
  • Rune Majlund Dahl
Underlyings
Bakkafrost P/F

Betsson AB Class B

Betsson AB is a holding company. Co.'s core business consists of investing and administering shareholdings in companies which - through partners or by themselves - offer games to end users via the internet. Co. owns Betsson Malta which operates games through partnerships and the own websites www.betsson.com, www.casinoeuro.com and www.cherrycasino.com. Betsson Malta offers Poker, Casino, Sports betting, Scratch Cards, Bingo and Games. Customers primarily originate from the Scandinavian countries and other areas within Europe.

DOF ASA

DOF is the parent company in DOF's group of companies which owns and operates a fleet of supply and subsea vessels as well as having the engineering capacity to service the subsea market. Co. operates worldwide and provides services to the global oil and gas industry. Co. operates in three segments of the offshore service market. These are defined by types of activities and vessel types: Platform Supply Vessels, Anchor Handling Tug Supply Vessels and Subsea Vessels and Subsea Engineering. The subsea engineering activities among others comprise Survey and Positioning, Inspection, Repair and Maintenance Services, Construction Support, Diving Services and Mooring Projects.

GasLog Ltd.

Targovax AS

Targovax ASA is a Norway-based company active within the healthcare sector. The Company is developing two complementary and targeted approaches in immuno-oncology: a peptide-based immunotherapy platform for patients with RAS-mutated cancers and a virus-based immunotherapy platform based on engineered oncolytic viruses armed with potent immune-stimulating transgenes for patients with solid tumors. The Company's candidate, TG01, is a peptide vaccine that targets mutations in the RAS genes that are associated with cancer, and it is in a phase II clinical trial in pancreatic cancer. The Company's other RAS targeting immunotherapy, TG02 is developed for colorectal cancer treatment. The Company's adenoviral candidate, ONCOS-102 is developed for the treatment of solid tumors, such as melanoma as well as ovarian and prostate cancer.

Provider
DnB Markets
DnB Markets

DNB Markets is the investment banking arm of DNB Bank ASA and is focused primarily on the Nordic region, as well as internationally on niches such as global shipping, energy and related services, and seafood. DNB Markets offers services in FICC, Equities and Investment Banking advisory from offices in Oslo, Stockholm, London, Singapore and New York. Equity research coverage is offered on c250 Nordic companies. DNB was ranked no.2 in Extel Nordic Research 2017. The DNB Markets’ Credit and FICC Macro & FX Research teams are repeatedly highly rated by Prospera Nordic Institutional Investor Surveys.

 

Analysts
Alexander Aukner

Karl-Johan Bonnevier

Martin Arnell

Mats Bye

Nicolai Farstad Olsen

Ole-Andreas Krohn

Patrik Ling

Rune Majlund Dahl

Other Reports on these Companies
Other Reports from DnB Markets
Alexander Aukner
  • Alexander Aukner
Alexander Aukner
  • Alexander Aukner
Alexander Aukner
  • Alexander Aukner

ResearchPool Subscriptions

Get the most out of your insights

Get in touch